We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Rapid Blood Test Detects Breast Cancer Markers within 20 Minutes

By LabMedica International staff writers
Posted on 01 Feb 2024
Print article
Image: Researcher Aleksei Kuzin holding the photonic chip that is the sensing component in the new diagnostic platform (Photo courtesy of Skoltech)
Image: Researcher Aleksei Kuzin holding the photonic chip that is the sensing component in the new diagnostic platform (Photo courtesy of Skoltech)

Small extracellular vesicles (sEVs) are biomarkers for breast cancer and take the form of tiny bubbles ranging from 20 to 150 nanometers in size. These vesicles play a crucial role in substance transport and cell communication within the body. Found in blood and other body fluids, sEVs carry various molecules that indicate the presence and stage of breast cancer, with their concentration being a key factor. The traditional method for measuring sEV levels relies on expensive animal-produced antibodies, making it both costly and time-intensive due to the preparation of bodily fluids. Additionally, the instability of antibodies adds to the complications. Now, scientists have developed a new method to diagnose breast cancer markers quickly, within just 15 to 20 minutes, using a minimal amount of blood sample.

The supersensitive system developed by a team of scientists, including researchers from Skoltech (Moscow, Russia), combines photonic sensors and microfluidics to spot breast cancer early on, thereby allowing timely intervention and evaluation of treatment efficacy. The blood test is conducted on a microchip that identifies the sEVs. To gauge the concentration of sEVs, the system utilizes photonic microsensors, which are microchips carrying signals through light particles or photons. The fluid under analysis flows through a very narrow channel, whose walls are coated with specialized 'target' molecules [DARPins] at the intersection with the waveguide carrying light. As the vesicles pass, they adhere to these molecules, and their quantity affects how light moves along the waveguide, a change that is measurable.

According to the researchers, the approach offers several benefits. The molecules deposited on the microchannel walls are smaller and less expensive than antibodies, and the photonic integrated circuits have a relatively simple design to facilitate future mass production. This new breast cancer screening technique could make the procedure more accessible and cost-effective. The device's microtubes are washable, and its sensor’s active layer can be re-applied for reuse. However, experts caution that sEVs are not solely linked to cancer, as all cells produce them in varying quantities based on the body's condition, such as health status and diet. Therefore, careful application of this method is crucial to avoid false positives or negatives.

Nevertheless, the test's simplicity makes it suitable for routine medical examinations. Early detection and appropriate responses could lead to more favorable outcomes. The method’s potential extends to diagnosing other diseases, indicating its scalability. In the future, the device might even facilitate simultaneous screening for multiple diseases. Additionally, the possibility of analyzing other bodily fluids, like urine, may be incorporated as the technology advances. However, while the microchip itself could be inexpensive, the required analysis device might be costly and need specialized operators. The conservative nature of healthcare, often favoring infrastructurally convenient solutions that integrate with existing hardware and do not require personnel retraining, is an important factor in the development of new medical techniques and equipment. The researchers will now further develop the method taking into account its affordability and compatibility with the medical equipment routinely used in clinics.

“Breast cancer diagnostics is an actively developing area of Russian health care. The main advantages of the newly proposed method are the rapid test results, the small amount of biological fluid required, and the capacity for repeated use,” said Irina Shipunova, a senior research scientist at the National Medical Research Center of Hematology.

“Using biophotonics to detect oncomarkers, and tumor-specific microvesicles in particular, is a promising approach. Such solutions could make tests faster,” added Albert Rizvanov from Kazan Federal University.

Related Links:
Skoltech

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.